0001209191-20-058241.txt : 20201113
0001209191-20-058241.hdr.sgml : 20201113
20201113122932
ACCESSION NUMBER: 0001209191-20-058241
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201111
FILED AS OF DATE: 20201113
DATE AS OF CHANGE: 20201113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith David V
CENTRAL INDEX KEY: 0001229447
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36070
FILM NUMBER: 201310238
MAIL ADDRESS:
STREET 1: 6035 STONERIDGE DRIVE
CITY: PLEASANTON
STATE: CA
ZIP: 94588
FORMER NAME:
FORMER CONFORMED NAME: SMITH DAVID V
DATE OF NAME CHANGE: 20030429
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FIVE PRIME THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001175505
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 260038620
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 111 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 415-365-5600
MAIL ADDRESS:
STREET 1: 111 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: FIVE PRIME THERAPEUTICS INC
DATE OF NAME CHANGE: 20020613
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-11
0
0001175505
FIVE PRIME THERAPEUTICS, INC.
FPRX
0001229447
Smith David V
111 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Executive Vice President & CFO
Common Stock
2020-11-11
4
M
0
22000
0.00
A
85389
D
Common Stock
2020-11-11
4
F
0
10908
18.00
D
74481
D
Performance-Based Restricted Common Stock
2020-11-11
4
M
0
22000
0.00
D
Common Stock
22000
22000
D
Represents shares of performance-based restricted common stock granted to the reporting person on June 24, 2019. These shares vested on
the date that the 30-calendar-day volume-weighted average closing price of a share of common stock of Five Prime Therapeutics, Inc. (the
"Company") was greater than or equal to $12.95.
The shares subject to this grant vest upon achievement of certain performance conditions, as further described in the other footnotes to this
report.
Represents 50% of the shares subject to this award, which shares vested on the date that the 30-calendar-day volume-weighted average closing
price of a share of common stock of the Company was greater than or equal to $12.95.
The remaining shares subject to this award will vest on the date that the 30-calendar-day volume-weighted average closing price of a share of
common stock of the Company is greater than or equal to $19.43, subject to the reporting person's continued service to the Company through such date; provided that such shares shall automatically expire and be forfeited if such
shares have not vested by December 31, 2021.
/s/ Francis Sarena, Attorney-in-fact
2020-11-13